Physician profile
Munawar Alavi
NPI 1851334403
$2,049.88
in general payments reported to CMS, 2019-2025
19 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $153 · 2021: $145 · 2022: $265 · 2023: $355 · 2024: $345 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.15 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $356.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $174.26 | 2022-2025 | Eliquis |
| Pfizer INC. | $150.60 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.67 | 2024-2025 | |
| Medtronic, INC. | $114.88 | 2022 | |
| Amgen INC. | $108.84 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $105.92 | 2019 | |
| Abbott Laboratories | $104.32 | 2021-2025 | Cardiomems, Mitraclip |
| Baxter Healthcare | $93.23 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $92.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $86.88 | 2019-2021 | |
| Bardy Diagnostics, INC. | $82.46 | 2020 | |
| Boston Scientific Corporation | $74.51 | 2022-2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $49.87 | 2023 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $30.53 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $26.12 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $24.71 | 2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $18.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munawar Alavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.